← Back to Analyst Consensus 
ATRA Buy
Atara Biotherapeutics, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 18, 2026 | Freedom Broker | upgrade | Sell → Hold | — | 59% |
| May 8, 2026 | Canaccord Genuity | upgrade | Hold → Buy | — | 48% |
| Jan 21, 2026 | Freedom Broker | downgrade | Buy → Sell | — | 59% |
| Jan 13, 2026 | Canaccord Genuity | downgrade | Buy → Hold | $6 | 48% |
| Dec 19, 2025 | Canaccord Genuity | maintain | Buy → Buy | $25 | 48% |
| Mar 11, 2025 | Canaccord Genuity | maintain | Buy → Buy | $17 | 48% |
| Jan 22, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Jan 17, 2025 | Canaccord Genuity | maintain | Buy → Buy | $17 | 48% |
| Dec 20, 2024 | Rodman & Renshaw | initiate | — → Buy | $25 | 40% |
| Nov 13, 2024 | Canaccord Genuity | maintain | Buy → Buy | $21 | 48% |
| Aug 21, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Aug 16, 2024 | Mizuho | upgrade | Neutral → Outperform | $18 | 52% |
| Aug 13, 2024 | Canaccord Genuity | maintain | Buy → Buy | $13 | 48% |
| Jul 17, 2024 | Goldman Sachs | maintain | Sell → Sell | $11 | 54% |
| May 22, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Apr 1, 2024 | Stifel | maintain | Hold → Hold | $2.3 | 53% |
| Nov 10, 2023 | Goldman Sachs | maintain | Sell → Sell | $0.5 | 54% |
| Nov 9, 2023 | Evercore ISI Group | downgrade | Outperform → In-Line | $0 | 58% |
| Nov 9, 2023 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Nov 9, 2023 | Mizuho | downgrade | Buy → Neutral | $1 | 52% |
| Sep 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Aug 21, 2023 | Citigroup | maintain | Sell → Sell | $1.4 | 54% |
| Aug 9, 2023 | EF Hutton | reiterate | Buy → Buy | $25 | 30% |
| Jun 14, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $28 | 44% |
| May 9, 2023 | Canaccord Genuity | maintain | — → Buy | $20 | 48% |
| Feb 9, 2023 | EF Hutton | reiterate | — → Buy | $25 | 30% |
| Feb 9, 2023 | HC Wainwright & Co. | maintain | — → Buy | $27 | 44% |
| Feb 7, 2023 | Mizuho | reiterate | — → Buy | $31 | 52% |
| Jan 5, 2023 | EF Hutton | initiate | — → Buy | $25 | 30% |
| Aug 16, 2022 | Mizuho | maintain | — → Buy | $31 | 52% |
| Aug 9, 2022 | Goldman Sachs | maintain | — → Sell | $3 | 54% |
| Jul 20, 2022 | Citigroup | downgrade | Neutral → Sell | $3 | 54% |
| Jul 13, 2022 | JP Morgan | downgrade | Overweight → Neutral | $10 | 54% |
| Jul 13, 2022 | Stifel | downgrade | Buy → Hold | $5 | 53% |
| May 24, 2022 | Goldman Sachs | maintain | — → Sell | $4 | 54% |
| May 23, 2022 | HC Wainwright & Co. | maintain | — → Buy | $29 | 44% |
| May 10, 2022 | Citigroup | downgrade | Buy → Neutral | $8 | 54% |
| Mar 28, 2022 | JP Morgan | maintain | — → Overweight | $22 | 54% |
| Jan 3, 2022 | JP Morgan | maintain | — → Overweight | $27 | 54% |
| May 13, 2021 | JP Morgan | upgrade | Neutral → Overweight | $29 | 54% |
| May 5, 2021 | HC Wainwright & Co. | maintain | — → Buy | $31 | 44% |
| Dec 8, 2020 | HC Wainwright & Co. | maintain | — → Buy | $31 | 44% |
| Nov 10, 2020 | HC Wainwright & Co. | maintain | — → Buy | $28 | 44% |
| Sep 15, 2020 | Canaccord Genuity | maintain | — → Buy | $78 | 48% |
| Aug 6, 2020 | Stifel | maintain | — → Buy | $28 | 53% |
| Aug 6, 2020 | HC Wainwright & Co. | maintain | — → Buy | $26 | 44% |
| Jun 30, 2020 | Evercore ISI Group | initiate | — → Outperform | $0 | 58% |
| Jun 15, 2020 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
| May 12, 2020 | JP Morgan | maintain | — → Neutral | $23 | 54% |
| Apr 23, 2020 | Citigroup | upgrade | Neutral → Buy | $0 | 54% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days